Safety and efficacy of amiodarone and dronedarone for early rhythm control in EAST-AFNET 4.

• Tác giả: Katrin Borof, Günter Breithardt, A John Camm, Harry Crijns, Lars Eckardt, Larissa Fabritz, Andreas Goette, Hein Heidbüchel, Paulus Kirchhof, Marc D Lemoine, Christina Magnussen, Andreas Metzner, Andreas Rillig, Laura Rottner, Renate B Schnabel, Ulrich Schotten, Stephan Willems, Antonia Zapf
• Ngôn ngữ: eng
• Ký hiệu phân loại: 152.1 Sensory perception
• Thông tin xuất bản: Germany : Clinical research in cardiology : official journal of the German Cardiac Society , 2025
• Bộ sưu tập: NCBI
• ID: 750217

Tóm tắt

AIMS: Concerns exist about the safety of amiodarone and dronedarone. We assessed the long-term outcome of both drugs for early rhythm control (ERC) in the EAST-AFNET 4 trial. METHODS AND RESULTS: Patients randomized for ERC and treated with amiodarone or dronedarone were compared to other ERC-therapies. Patients receiving amiodarone or dronedarone at initial therapy (n = 653/1395) were older with more comorbidities and less paroxysmal atrial fibrillation (AF, 29%) compared to patients never receiving amiodarone or dronedarone (Amiodarone/Dronedarone CONCLUSION: Early rhythm control using amiodarone or dronedarone rarely led to drug-related serious adverse events in EAST-AFNET 4. CLINICAL TRIAL REGISTRATION: ISRCTN04708680, NCT01288352, EudraCT2010-021258-20.